The Neurofibromatosis Therapeutic Consortium (NFTC) brought together four labs to find novel targets for clinical trials. These two consortia cooperated to perform and complete 111 preclinical trials across different models. These studies identified 12 drug targets with promising efficacy, and 16 clinical trials have occurred based on the veracious preclinical data gathered by NFPC and NFTC investigators.

Mission

The NFTC was focused on NF1 and included sites investigating animal models of plexiform neurofibromas, MPNSTs, and NF1-associated leukemia. To continue the NFPC’s work on NF2, the Foundation launched the Synodos initiative.
The Neurofibromatosis Therapeutic Consortium (NFTC) was launched at the conclusion of the NFPC as a three year $4 million program to follow up the work of the NFPC. The NFTC was focused on NF1 and included sites investigating animal models of plexiform neurofibromas, MPNSTs, and NF1-associated leukemia. To continue the NFPC’s work on NF2, the foundation launched the Synodos initiative.

### Structure & Governance

The NFTC was created and run by the Children’s Tumor Foundation and then continued as the Synodos initiative.

### Financing

This three-year, $4 million collaboration was co-funded with NTAP (Neurofibromatosis Therapeutic Acceleration Program) and was an extension of the Neurofibromatosis Preclinical Consortium (NFPC), a five-year, $7 million program that concluded in 2013.

### Intellectual Property

Children’s Tumor Foundation - All rights reserved

### Data Sharing

The Donor Privacy Policy is an official policy approved by the Children’s Tumor Foundation Board of Directors. The Children’s Tumor Foundation maintains the highest level of respect for the privacy of our donors. The foundation does not sell, trade, or rent donor data. Further information on specific aspects of the foundation’s commitment to protecting your information is provided below.
Impact/Accomplishment

Studies identified 12 drug targets with promising efficacy, and 16 clinical trials have occurred based on the veracious preclinical data gathered by NFPC and NFTC investigators.

Links/Social Media Feed

Homepage: http://www.ctf.org/research/nf-therapeutic-consortium
Twitter: @ChildrensTumor
Facebook: @childrenstumor

Points of Contact

Toll-free: 1-800-323-7938
E-mail: info@ctf.org

120 Wall Street, 16th Floor
New York, NY 10005-3904
Office: 212-344-6633
Fax: 212-747-0004

Sponsors & Partners

Benjamin Braun, University of California
Karen Cichowski, Harvard Medical School/Brigham and Women’s Hospital
D. Wade Clapp, Indiana University School of Medicine
Nancy Ratner, Cincinnati Children’s Hospital Medical Center